Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06487286
Recruiting Observational

Levels of Visfatin/NAMPT in Human Milk

NCT06487286 · tracked via the Priya Life Science Italy tracker
Sponsor
Paolo Manzoni Study Group
Phase
Observational
Started
2024-10-24
Last updated
2024-11-14

Condition(s) studied

Visfatin Levels in Maternal Milk SamplesBirth Weight

Investigational drug(s) / intervention(s)

observational study

observational study: observational study

Study summary

Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities * Maternal hospitalization * Acquisition of the informed consent form signed by the patient Exclusion Criteria: * Refusal of the patient to participate in the study * Presence of hypogalactia or agalactia in the patient

Primary outcome measure(s)

  • Visfatin levels — 48 hours, 7 days and 30 days
    Visfatin levels in maternal milk samples
  • Visfatin levels — 1-2 days post-partum
    Visfatin levels in maternal plasma/serum

Trial sites (1)

FacilityCityRegionStatus
Ospedale degli Infermi - ASL BI Ponderano BI Recruiting

More Paolo Manzoni Study Group trials in Italy

Use of a Silicone Sensor to Protect Fragile Neonatal Skin in Moderately Preterm Infants Needing Continuous Monitoring Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06487286 on ClinicalTrials.gov ↗ ← All trials in Italy